NICE Annual Conference
Sharon Deveson Kell attended the National Institute for Health and [...]
NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) has [...]
Adjuvant pembrolizumab approved by NICE
Late last week we learnt that the National Institute for [...]
Adjuvant pembrolizumab gets positive opinion from the European CHMP
We have just learnt that the Committee for Medicinal Products [...]
NHS England unveils new Innovative Medicines Fund
NHS England has launched its new Innovative Medicines Fund (IMF). [...]
Pembrolizumab plus axitinib combination declined for first-line treatment of advanced kidney cancer
The National Institute for Health and Care Excellence (NICE) have issued [...]
Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer
KCSN are formal consultants to NICE and part of the [...]
COVID-19: Doctors given new guidelines for treating patients in critical care
Amid concerns that the NHS will be overwhelmed by the [...]
NICE draft guidance refuses pembrolizumab plus axitinib combination
The National Institute for Health and Care Excellence (NICE) have issued [...]
Research supports better integration of patient voice in health technology assessments
A report from Myeloma UK and the National Institute for [...]
